The Daily Folgen

For decades, drugmakers have argued that patents are critical to bringing new drugs to the market. But in 2004, when a promising H.I.V. treatment emerged, Gilead Sciences decided to slow-walk its release to maximize profit on the company’s existing patents.Rebecca Robbins, who covers the pharmaceutical industry for The Times, discusses one man’s case and how patents can create perverse incentives to delay new and better drugs.Guest: Rebecca Robbins, a business reporter covering the pharmaceutical industry for The New York Times.Background reading: Gilead delayed a new version of a drug, allowing it to extend the patent life of a blockbuster line of medications, internal documents showed.In August, an expert panel recommended the new daily pill Descovy for H.I.V. prevention.For more information on today’s episode, visit nytimes.com/thedaily. Transcripts of each episode will be made available by the next workday. Subscribe today at nytimes.com/podcasts or on Apple Podcasts and Spotify. You can also subscribe via your favorite podcast app here https://www.nytimes.com/activate-access/audio?source=podcatcher. For more podcasts and narrated articles, download The New York Times app at nytimes.com/app. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In New York, the arrival of more than 100,000 migrants seeking asylum over the past year has become a crisis for the city’s shelter system, schools and budget.As another critical election season begins to take shape, Nicholas Fandos, who covers New York State politics for The Times, explains why the situation has also become a political crisis for the state’s Democratic leaders.Guest: Nicholas Fandos, a reporter covering New York State politics for The New York Times Metro desk.Background reading: New York’s migrant crisis is growing. So are Democrats’ anxieties.A scathing letter revealed tension among New York Democrats over the city’s migrant crisis.For more information on today’s episode, visit nytimes.com/thedaily. Transcripts of each episode will be made available by the next workday.  Subscribe today at nytimes.com/podcasts or on Apple Podcasts and Spotify. You can also subscribe via your favorite podcast app here https://www.nytimes.com/activate-access/audio?source=podcatcher. For more podcasts and narrated articles, download The New York Times app at nytimes.com/app. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

A Times investigation found that U.S. passenger planes come dangerously close to crashing into each other far more frequently than the public knows.Sydney Ember, an economics reporter for The Times, explains why an aviation system known for its safety is producing such a steady stream of close calls.Guest: Sydney Ember, an economics correspondent for The New York Times.Background reading: Airline close calls happen far more often than previously known.What you need to know about turbulence.For more information on today’s episode, visit nytimes.com/thedaily. Transcripts of each episode will be made available by the next workday. Subscribe today at nytimes.com/podcasts or on Apple Podcasts and Spotify. You can also subscribe via your favorite podcast app here https://www.nytimes.com/activate-access/audio?source=podcatcher. For more podcasts and narrated articles, download The New York Times app at nytimes.com/app. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.